Clinsight
1 in 41 men die from Prostate cancer, Clinsight want to change that.
There is a need to standardize and increase the accuracy of diagnosis and Gleason-grading in prostate cancer for healthcare.
Clinsight are in the final stages of having a fully validated AI prototype that will diagnose and Gleason-grade prostate cancer with the same level of accuracy as expert uro-pathologists.
The solutions will be seamlessly integrated into the digital pathology workflow to help pathologists in their assessment.
Clinsight AI system springs from world leaders in prostate pathology and artificial intelligence development in precision medicine.
https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(19)30738-7/fulltext